Literature DB >> 12825548

Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fisher 344 male rats [Mechanisms of Ageing and Development 123 (2002) 1665-1680].

In Kyoung Lim1.   

Abstract

UNLABELLED: Unlike other tissues such as breast, colon and renal cell carcinoma, it is not an easy task to single out any representative oncogene or tumor suppressor genes in the development of hepatocellular carcinoma (HCC), which play a pivotal role. To investigate putatively altered main pathways in HCC, F344 male rats were treated with a single injection of N-nitrosodiethylamine (DEN), followed by either twice/week injections of nodularin for 10 weeks or thioacetamide (TAA) in drinking water for 39 weeks. p53 expression was dramatic in both hepatocytes and mesenchymal cells after a single injection of DEN, however, PCR-SSCP assay could not detect any p53 mutation during the development of hepatocellular adenoma (HCA). The data indicate that wtp53 response was mostly for removal of damaged cells during the initiation of carcinogenesis. When treated with DEN-TAA, induction of gankyrin expression during hepatic fibrosis preceded the loss of pRB protein, accompanied with significant expressions of G1phase cyclins and CDKs. Moreover, p16(INK4A) exon 1 was hypermethylated during the development of poorly differentiated HCCs. These changes would result in complete inactivation of the pRB regulatory pathway during hepatocarcinogenesis. Induction of TGF-beta1 expression with loss of its receptor expression occurred rapidly in the altered hepatocytes by DEN-nodularin treatment.
CONCLUSION: Therefore, escape from TGF-beta1 induced apoptosis and severe degradation of pRB protein during the early stage of carcinogenesis can perform a symphony to proliferate and to transform the altered hepatocytes to tumor cells. Inactivation of p16(INK4A) and p53 genes at the later stage of carcinogenesis would endow HCC with malignancy, which is highly resistant to any therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825548     DOI: 10.1016/s0047-6374(03)00010-1

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  9 in total

1.  FXR-Gankyrin axis is involved in development of pediatric liver cancer.

Authors:  Leila Valanejad; Kyle Lewis; Mary Wright; Yanjun Jiang; Amber D'Souza; Rebekah Karns; Rachel Sheridan; Anita Gupta; Kevin Bove; David Witte; James Geller; Gregory Tiao; David L Nelson; Lubov Timchenko; Nikolai Timchenko
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

Review 2.  Intracellular signaling and hepatocellular carcinoma.

Authors:  Polina Iakova; Lubov Timchenko; Nikolai A Timchenko
Journal:  Semin Cancer Biol       Date:  2010-09-17       Impact factor: 15.707

3.  Elimination of C/EBPalpha through the ubiquitin-proteasome system promotes the development of liver cancer in mice.

Authors:  Guo-Li Wang; Xiurong Shi; Simon Haefliger; Jingling Jin; Angela Major; Polina Iakova; Milton Finegold; Nikolai A Timchenko
Journal:  J Clin Invest       Date:  2010-07       Impact factor: 14.808

4.  Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.

Authors:  Anjali Mahajan; Yi Guo; Chunhua Yuan; Christopher M Weghorst; Ming-Daw Tsai; Junan Li
Journal:  J Mol Biol       Date:  2007-08-22       Impact factor: 5.469

Review 5.  Epidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Alexander Neusner; Jennifer Chu; Margot Lawton
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

7.  Upregulated microRNA-92b regulates the differentiation and proliferation of EpCAM-positive fetal liver cells by targeting C/EBPß.

Authors:  Nian-Song Qian; Wei-Hui Liu; Wen-Ping Lv; Xin Xiang; Ming Su; Vikram Raut; Yong-Liang Chen; Jia-Hong Dong
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

8.  Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.

Authors:  Christian Liedtke; Tom Luedde; Tilman Sauerbruch; David Scholten; Konrad Streetz; Frank Tacke; René Tolba; Christian Trautwein; Jonel Trebicka; Ralf Weiskirchen
Journal:  Fibrogenesis Tissue Repair       Date:  2013-10-01

9.  Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.

Authors:  Amber M D'Souza; Yanjun Jiang; Ashley Cast; Leila Valanejad; Mary Wright; Kyle Lewis; Meenasri Kumbaji; Sheeniza Shah; David Smithrud; Rebekah Karns; Soona Shin; Nikolai Timchenko
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-05-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.